The """"""""Best Pharmaceuticals for Children/Pediatric Devices"""""""" Act was signed into law by the President on September 27th 2007 (P.L. 110-85). The legislation was reauthorized as part of the FDA Amendments Act of 2007 (P.L. 110-85), extending patent exclusivity and making improvements to the research program led by the NICHD in partnership with other NIH Institutes, Centers and the Foundation of the NIH (FNIH). The steps NIH has taken to implement the new legislation include;redirecting prioritization to focus on needs in pediatric therapeutics, identification of gaps in testing drugs and bilogics, identification of diseases and conditions bringing children into contact with the health care system and therapeutic approaches utilized in treating those diseases and conditions. This agreement provides funds for the FY 2011 implementation of the Best Pharmaceuticals for Children Act (BPCA), supporting the scientific research related to pediatric therapeutics.
